SCHEMBL9507272

SCHEMBL9507272

CCOC(=O)C(C)CCC(C)O

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.40
CYP3A4 P08684 1/20 0.39
CYP2C19 P33261 1/20 0.39
LMNA P02545 1/20 0.39
HSD17B10 Q99714 1/20 0.39
GAA P10253 2/20 0.38
ALOX15 P16050 1/20 0.37
MGAM O43451 1/20 0.37
SI P14410 1/20 0.37
MGAM2 Q2M2H8 1/20 0.37
SOAT1 P35610 1/20 0.37
MEN1 O00255 1/20 0.35
NPC1 O15118 1/20 0.35
KMT2A Q03164 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
METAP2 P50579 2/20 0.35
METAP1 P53582 1/20 0.35
TRPA1 O75762 1/20 0.34
CPB2 Q96IY4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14616914 0.91 ALDH1A1 (0.48) ALDH1A1CYP3A4CYP2C19LMNAHSD17B10
SCHEMBL7530179 0.84 GABRR1 (0.50) ALDH1A1CYP3A4CYP2C19LMNAHSD17B10
SCHEMBL7843927 0.84 ALDH1A1 (0.42) ALDH1A1CYP3A4CYP2C19LMNAHSD17B10
SCHEMBL9507495 0.83 HSD17B10 (0.40) ALDH1A1LMNAHSD17B10MEN1KMT2A
SCHEMBL8245481 0.81 SMN1; SMN2 (0.45) ALDH1A1CYP3A4CYP2C19LMNAHSD17B10
SCHEMBL28182020 0.81 ALDH1A1 (0.43) ALDH1A1CYP3A4CYP2C19LMNAHSD17B10
SCHEMBL13483255 0.81 SMN1; SMN2 (0.45) ALDH1A1CYP3A4CYP2C19LMNAHSD17B10
SCHEMBL113543 0.81 SMN1; SMN2 (0.45) ALDH1A1CYP3A4CYP2C19LMNAHSD17B10
SCHEMBL9509815 0.80 TSHR (0.42) ALDH1A1
SCHEMBL9507791 0.79 ALDH1A1 (0.47) ALDH1A1NPC1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12037320-B2 Pro-benefit-agent compounds with heterocyclic moieties THE PROCTER & GAMBLE COMPANY (US) 2024-07-16 US disclosed
EP-0388960-B1 OPTICALLY ACTIVE COMPOUNDS AND THEIR PREPARATION AND USE HITACHI, LTD. (JP) 1993-10-06 EP disclosed
US-5152919-A Stability, chemical resistance, high speed response, large spo ntaneous polarization, molecular orientation and wide temperat ure range HITACHI, LTD. (JP) 1992-10-06 US disclosed
EP-0388960-A1 Optically active compounds and their preparation and use HITACHI, LTD. (JP) 1990-09-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12037320-B2 Pro-benefit-agent compounds with heterocyclic moieties PLG, PAM, PREP ALDH1A1 151/4885CYP3A4 1520/4885CYP2C19 531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.